A new MedTech Unboxed episode is out now with Christopher Haig, President of Efemoral Medical, a company developing bioresorbable scaffolds for treating peripheral arterial disease (PAD), affecting over 200 million globally. Here’s a snapshot of our discussion:
- FlexStep Technology: A balloon-expandable, drug-eluting bioresorbable scaffold with inter-scaffold spaces for flexibility, made of PLLA with a co-polymer for ductility and rapid resorption (1-2 years), eluting sirolimus to prevent restenosis.
- Clinical Progress: The EFEMORAL I trial (33 patients enrolled across 4 sites in New Zealand/Australia) shows promise, with 20-patient results to be presented by Dr. Andrew Holden at @CXSymposium in London, April 23, 2025.
- Funding Update: Raised $10M+ in equity through angel investors and $2M+ in SBIR grants; targeting $20M Series B for IDE submission, including GLP animal studies and randomized trials for US PMA approval.
